Debate Dossier
Bioethics · Live Motion
Should Genetic Engineering of Humans Be Allowed?
A bioethics motion that turns on whether therapy and enhancement can be drawn as separate categories in practice.
FormatQuick Clash / BP / PF adaptable
DifficultyHard
Main clashTherapy and enhancement vs equity and consent
Best forBioethics, Category lines, Future tech
The round turns on this
Can therapy and enhancement be drawn as separate categories in practice?
Allow therapy
- Heritable disease elimination is a moral imperative
- Existing therapies (gene therapy, IVF screening) already cross the line
- Categorical bans push the work into less-regulated jurisdictions
Hard line
- Therapy-enhancement drift is documented
- Consent of future generations is impossible
- Inequity of access converts the technology into a new class divide
Category separability is the round.
Argument arena · prep both sides
Pro
A regulated therapy regime that prevents heritable disease is the moral floor of a society that has the tool.
PRO 1 Disease elimination
ClaimCystic fibrosis, Huntington's, and sickle cell are heritable and treatable at the embryo stage.
WarrantCRISPR and PGT-M are the mature tools; clinical pilots exist.
ImpactYou eliminate suffering you have the tool to prevent.
Attack this
Con will say the same tool unlocks the enhancement door.
PRO 2 Categorical ban displaces
ClaimA blanket ban does not stop the research; it relocates it.
WarrantThe He Jiankui case shows what unregulated displacement looks like.
ImpactYou get the worst version of the technology with none of the oversight.
Attack this
Con will say displacement is no worse than rapid domestic adoption.
VS
Con
The therapy-enhancement line cannot be drawn in practice and the inequity of access turns the technology into a class divide.
CON 1 Therapy drifts to enhancement
ClaimIVF screening already includes traits beyond disease.
WarrantDocumented expansion of polygenic-screening companies.
ImpactThe categorical line Pro promises has already failed in the cleanest current case.
Attack this
Pro will say screening is selection, not engineering.
CON 2 Equity collapse
ClaimTherapy-grade genetic engineering will be priced out of public health systems for at least a generation.
WarrantExisting precision medicine is the case study.
ImpactYou produce a heritable class divide.
Attack this
Pro will say public-health subsidies and price controls address this layer.
Sample round · flowed with judge notes
Pro · openingStrong open
Cystic fibrosis, Huntington's, sickle cell. Three heritable diseases the tool can prevent. A society with the tool is morally responsible for using it under oversight.
JudgeStrong moral floor.
Con · responseBest turn
IVF screening already includes traits beyond disease. The categorical line Pro promises has already failed in the cleanest current case.
JudgeSharp drift turn.
Pro · rebuttalPatches
Screening is selection, not engineering. The cases are different in kind; the regulatory regime can hold the line because the underlying methods differ.
JudgePatches the distinction.
Con · weighingBest weigh
Selection and engineering produce the same outcome (designed offspring). The regulatory category is downstream of the social demand, and the demand is the same.
JudgeConnects via demand.
Judge ballot
Con wins
Narrow margin
Reason for decision
Pro's moral-floor opening is genuinely persuasive. Con holds the round on the social-demand argument Pro never separates from the technological distinction.
Key clash
Whether the therapy-enhancement line is technically or socially drawn.
Pro · feedback
You needed a regulatory mechanism (registry, indication list) that ties the line to a concrete enforcement surface.
Con · feedback
Excellent demand-driven extension. The IVF case study anchored the round.
One drill before the rematch